AU2014202896A1 — Topical formulation for a jak inhibitor
Assigned to Incyte Holdings Corp · Expires 2014-06-19 · 12y expired
What this patent protects
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 5 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. WO 2…
USPTO Abstract
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1 5 yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders. WO 2011/146808 PCT/US2011/037291 PARABEN PHASE PropyleneGyo ACTIVEUSPHASE Methyl Paraben -Fix NF Purified Water Propyl Paraben NF Mix Edetate Disodium Polyethylene Glycol USP Mix ACTIVE PHASE API P osphte 0 MixXANTHAN Propylene Glycol Light Mineral Oil USP Glyceryl Stearate XnhnGmN Polysorbate 20 NF Mx/Heat White Petrolatum i ___,:::Mix Cetyl Alcohol NF Emulsify Stearyl Alcohol NF Peoytao Dimethicone 360 t t Mix /Cool Medium Chain Triglycerides In Process Test Content Uniformity Topical formulation SFill in Tubes
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.